None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adults aged between 40 and 75 years (inclusive). 2.Individuals who meet the American College of Rheumatology classification criteria for osteoarthritis of the knee and satisfy both of the following conditions: ? Report unilateral or bilateral knee joint pain during weight-bearing activities within the past 6 months. ? Report a pain score of 40 mm or higher on a 100 mm Visual Analog Scale (VAS) due to knee joint pain. 3.Individuals with intact thermal sensation and the ability to distinguish differences in temperature. 4.Individuals who voluntarily decide to participate in this clinical trial and provide written informed consent. 5.Individuals who are reliable, willing to cooperate for the duration of the 3-month study period, and able to comply with the study requirements.
Exclusion criteria
Exclusion criteria: 1.History of knee joint trauma within the past 6 months. 2.History of knee joint surgery within the past 6 months. 3.Received intra-articular injection therapy (e.g., steroids, hyaluronic acid, prolotherapy, PRP [Platelet-Rich Plasma], etc.) within the past 3 months. 4.Use of medications such as opioid analgesics, anticonvulsants, or corticosteroids for pain control within the past 1 week. 5.Suspected inflammatory arthritis such as rheumatoid arthritis, infectious diseases, or autoimmune diseases based on physical examination or diagnostic medical tests. 6.Presence of physical or mental illness that may interfere with electrothermal acupuncture or device-based stimulation (e.g., severe cardiovascular or respiratory diseases, peripheral neuropathy due to diabetes). 7.Presence of neurological disorders such as local or generalized sensory paralysis. 8.Pregnant or breastfeeding women. 9.Individuals who have a fear of, adverse reactions to, or are expected to have adverse reactions to Electric Warm-Needling Therapy or Moxibustion Therapy 10.Any other case deemed unsuitable forElectric Warm-Needling Therapy or Moxibustion Therapy by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain NRS | — |
Secondary
| Measure | Time frame |
|---|---|
| K-WOMAC score;100mm Pain VAS ;PGIC score;EQ-5D score; Adverse reaction evaluation | — |
Countries
Korea, Republic of
Contacts
Dongguk University Bundang Oriental Hospital